LT2760479T - Azotą pašalinantis vaistas, skirtas naudoti azoto užlaikymo sutrikimo gydymo būde - Google Patents

Azotą pašalinantis vaistas, skirtas naudoti azoto užlaikymo sutrikimo gydymo būde

Info

Publication number
LT2760479T
LT2760479T LTEP12835407.3T LT12835407T LT2760479T LT 2760479 T LT2760479 T LT 2760479T LT 12835407 T LT12835407 T LT 12835407T LT 2760479 T LT2760479 T LT 2760479T
Authority
LT
Lithuania
Prior art keywords
nitrogen
treating
scavenging drug
retention disorder
disorder
Prior art date
Application number
LTEP12835407.3T
Other languages
English (en)
Inventor
Bruce Scharschmidt
Masoud MOKHTARANI
Original Assignee
Horizon Therapeutics, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47892277&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2760479(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Horizon Therapeutics, Llc filed Critical Horizon Therapeutics, Llc
Publication of LT2760479T publication Critical patent/LT2760479T/lt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N31/00—Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods
    • G01N31/22—Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods using chemical indicators
    • G01N31/221—Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods using chemical indicators for investigating pH value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/4925—Blood measuring blood gas content, e.g. O2, CO2, HCO3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/17—Nitrogen containing
    • Y10T436/173845—Amine and quaternary ammonium
    • Y10T436/175383—Ammonia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Ecology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
LTEP12835407.3T 2011-09-30 2012-03-09 Azotą pašalinantis vaistas, skirtas naudoti azoto užlaikymo sutrikimo gydymo būde LT2760479T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161542100P 2011-09-30 2011-09-30
US201161564668P 2011-11-29 2011-11-29
PCT/US2012/028620 WO2013048558A2 (en) 2011-09-30 2012-03-09 Methods of therapeutic monitoring of nitrogen scavenging drugs

Publications (1)

Publication Number Publication Date
LT2760479T true LT2760479T (lt) 2017-07-10

Family

ID=47892277

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP12835407.3T LT2760479T (lt) 2011-09-30 2012-03-09 Azotą pašalinantis vaistas, skirtas naudoti azoto užlaikymo sutrikimo gydymo būde

Country Status (24)

Country Link
US (21) US8404215B1 (lt)
EP (2) EP3263102A1 (lt)
JP (2) JP6073898B2 (lt)
KR (2) KR102019000B1 (lt)
CN (2) CN107271696A (lt)
AU (2) AU2012316750B2 (lt)
BR (1) BR112014007357B1 (lt)
CA (1) CA2850391A1 (lt)
CL (1) CL2014000783A1 (lt)
CY (1) CY1119028T1 (lt)
DK (1) DK2760479T3 (lt)
ES (1) ES2629859T3 (lt)
HR (1) HRP20171063T1 (lt)
HU (1) HUE035220T2 (lt)
IL (2) IL231732A (lt)
LT (1) LT2760479T (lt)
MX (2) MX366197B (lt)
PL (1) PL2760479T3 (lt)
PT (1) PT2760479T (lt)
RS (1) RS56196B1 (lt)
SG (1) SG11201400781TA (lt)
SI (1) SI2760479T1 (lt)
WO (1) WO2013048558A2 (lt)
ZA (1) ZA201401851B (lt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2760479T (pt) 2011-09-30 2017-07-21 Horizon Therapeutics Llc Métodos de monitorização da terapêutica com fármacos eliminadores de azoto
DK2846791T3 (en) 2012-04-20 2017-03-27 Horizon Therapeutics Llc HPN-100 FOR USE IN TREATMENT OF NITROGEN RETENTION DISORDER
PT2922576T (pt) * 2012-11-21 2018-01-24 Horizon Therapeutics Llc Métodos de administração e avaliação de fármacos sequestradores de azoto para o tratamento de encefalopatia hepática
WO2015048818A1 (en) * 2013-09-30 2015-04-02 Hyperion Therapeutics, Inc. Diagnosing, grading, monitoring, and treating hepatic encephalopathy
SI2986325T1 (sl) * 2013-10-14 2020-02-28 Immedica Pharma Ab Postopki zdravljenja motenj ciklusa sečnine
ES2833294T3 (es) 2013-11-14 2021-06-14 Ultragenyx Pharmaceutical Inc Composiciones sólidas de triglicéridos y usos de las mismas
EP3137116B1 (en) 2014-04-30 2020-12-16 The Johns Hopkins University Dendrimer compositions and their use in treatment of diseases of the eye
ES2748294T3 (es) * 2014-06-04 2020-03-16 Immedica Pharma Ab Métodos para tratar trastornos del ciclo de la urea con el fin de prevenir crisis hiperamonémicas controlando los niveles de amoniaco en sangre
CA2957721C (en) 2014-08-13 2021-04-13 The Johns Hopkins University Selective dendrimer delivery to brain tumors
US20170119899A1 (en) 2015-10-29 2017-05-04 The Johns Hopkins University Compositions and methods for treatment of peroxisomal disorders and leukodystrophies
WO2017147193A1 (en) * 2016-02-22 2017-08-31 Horizon Therapeutics, Llc Treatment of urea cycle disorders in neonates and infants
US9914692B2 (en) * 2016-05-25 2018-03-13 Horizon Therapeutics, Llc Procedure for the preparation of 4-phenyl butyrate and uses thereof
JP6752748B2 (ja) 2017-03-30 2020-09-09 住友重機械工業株式会社 減速装置
JP7454945B2 (ja) * 2017-07-03 2024-03-25 アボット・ラボラトリーズ 血液中のユビキチンカルボキシ末端ヒドロラーゼｌ１レベルを測定するための、改善された方法
US20210130480A1 (en) * 2017-08-22 2021-05-06 Regeneron Pharmaceuticals, Inc. Methods of treating urea cycle disorders by interfering with glucagon receptor signaling
US10668040B2 (en) 2017-09-11 2020-06-02 Horizon Therapeutics, Llc Treatment of urea cycle disorders in neonates and infants
CA3163892A1 (en) 2019-12-04 2021-06-10 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for drug delivery to the eye
WO2022011061A1 (en) * 2020-07-07 2022-01-13 Acer Therapeutics Inc. Methods of administering taste masked phenylbutyrate and compositions therefor

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1004595A (en) 1911-05-25 1911-10-03 Sargents Sons Corp C G Carrier for washing-bowls.
US1018300A (en) 1911-06-12 1912-02-20 John Davidson Condensing steam-engine.
US3686238A (en) 1970-01-19 1972-08-22 Syntex Corp Glycerol esterified with 2-naphthyl-acetic acids and fatty acids
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4457942A (en) 1982-08-20 1984-07-03 Brusilow Saul W Process for waste nitrogen removal
US5635532A (en) 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
US5879657A (en) 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders
AU4858796A (en) 1995-02-07 1996-08-27 Saul W. Brusilow Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in treatment of various disorders
DE19805854C1 (de) 1998-02-13 1999-05-12 Claas Usines France Schalteinrichtung für Schneidmesser
US6219567B1 (en) * 1999-06-21 2001-04-17 Cardiox Corporation Monitoring of total ammoniacal concentration in blood
IT1317073B1 (it) 2000-12-12 2003-05-26 Mini Ricerca Scient Tecnolog Esteri dell'acido fenilbutirrico, procedimenti per la loro produzionee loro impiego terapeutico.
US20030195255A1 (en) 2002-04-12 2003-10-16 Summar Marshall L. Method for treating hepatic encephalopathies
US20040229948A1 (en) 2002-04-12 2004-11-18 Summar Marshall L. Method for preventing hepatic encephalopathic episodes
US6825384B1 (en) 2004-01-29 2004-11-30 The Nutrasweet Company Bromine free TEMPO based catalyst system for oxidation of primary and secondary alcohols using NaOCl as an oxidant
US20050273359A1 (en) 2004-06-03 2005-12-08 Young David E System and method of evaluating preoperative medical care and determining recommended tests based on patient health history and medical condition and nature of surgical procedure
CN1778963A (zh) * 2004-11-23 2006-05-31 苏州艾杰生物科技有限公司 血氨含量测定方法及血氨诊断试剂盒
ES2537974T3 (es) * 2004-11-26 2015-06-16 Ucl Business Plc Composiciones que comprenden ornitina y fenilacetato o fenilbutirato para el tratamiento de la encefalopatía hepática
US20060135612A1 (en) 2004-12-17 2006-06-22 U.S. Department Of Veterans Affairs Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent
US20070004805A1 (en) 2005-07-01 2007-01-04 Navinta Llc Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate
US20100016207A1 (en) 2005-11-10 2010-01-21 Wurtman Richard J Methods and Compositions for Raising Levels and Release of Gamma Aminobutyric Acid
US8094521B2 (en) 2007-02-28 2012-01-10 Nightingale Products LLC Caregiver personal alert device
CA2711807A1 (en) 2008-01-08 2009-07-16 Akthelia Pharmaceuticals Agonists for antimicrobial peptide systems
EP2330892B1 (en) 2008-04-29 2016-06-29 Horizon Therapeutics, Inc. Methods of treatment using ammonia-scavenging drugs
WO2009145323A1 (ja) 2008-05-30 2009-12-03 日産化学工業株式会社 多環式化合物を用いるアルコールの酸化方法
WO2010025303A1 (en) 2008-08-29 2010-03-04 Hyperion Therapeutics Dosing and monitoring patients on nitrogen-scavenging drugs
LT2330892T (lt) 2008-08-29 2016-11-25 Horizon Therapeutics, Inc. Gydymo būdai panaudojant vaistus - amoniako gaudykles
DK2456304T3 (en) 2009-07-24 2015-08-31 Baylor College Medicine METHODS OF MODULATING acids with branched chains and uses thereof
EP2594550B1 (en) 2010-07-16 2016-10-12 Tohoku University Method for oxidizing alcohols
EP2611470B1 (en) 2010-08-31 2017-08-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Porous polysaccharide scaffold comprising nano-hydroxyapatite and use for bone formation
PT2760479T (pt) 2011-09-30 2017-07-21 Horizon Therapeutics Llc Métodos de monitorização da terapêutica com fármacos eliminadores de azoto
EP2607366A1 (en) 2011-12-21 2013-06-26 Lunamed AG Glycerol phenyl butyrate esters
DK2846791T3 (en) 2012-04-20 2017-03-27 Horizon Therapeutics Llc HPN-100 FOR USE IN TREATMENT OF NITROGEN RETENTION DISORDER
PT2922576T (pt) 2012-11-21 2018-01-24 Horizon Therapeutics Llc Métodos de administração e avaliação de fármacos sequestradores de azoto para o tratamento de encefalopatia hepática
CN103304402B (zh) 2013-05-24 2015-04-22 苏州诚和医药化学有限公司 一种制备4-苯-1-丁酸的方法
WO2015048818A1 (en) 2013-09-30 2015-04-02 Hyperion Therapeutics, Inc. Diagnosing, grading, monitoring, and treating hepatic encephalopathy
SI2986325T1 (sl) 2013-10-14 2020-02-28 Immedica Pharma Ab Postopki zdravljenja motenj ciklusa sečnine
IN2013MU03442A (lt) 2013-10-30 2015-07-17 Lupin Ltd
ES2748294T3 (es) 2014-06-04 2020-03-16 Immedica Pharma Ab Métodos para tratar trastornos del ciclo de la urea con el fin de prevenir crisis hiperamonémicas controlando los niveles de amoniaco en sangre
WO2017147193A1 (en) 2016-02-22 2017-08-31 Horizon Therapeutics, Llc Treatment of urea cycle disorders in neonates and infants
US9914692B2 (en) 2016-05-25 2018-03-13 Horizon Therapeutics, Llc Procedure for the preparation of 4-phenyl butyrate and uses thereof
US20190076383A1 (en) 2017-09-08 2019-03-14 Horizon Therapeutics, Llc Methods for treating urea cycle disorders
US10668040B2 (en) 2017-09-11 2020-06-02 Horizon Therapeutics, Llc Treatment of urea cycle disorders in neonates and infants

Also Published As

Publication number Publication date
AU2017251691A1 (en) 2017-11-09
DK2760479T3 (en) 2017-07-17
KR20140094517A (ko) 2014-07-30
US10183004B2 (en) 2019-01-22
US20180221326A1 (en) 2018-08-09
US20160199334A1 (en) 2016-07-14
US20180263949A1 (en) 2018-09-20
SG11201400781TA (en) 2014-04-28
CN104039358A (zh) 2014-09-10
EP2760479A2 (en) 2014-08-06
US20180221327A1 (en) 2018-08-09
HUE035220T2 (hu) 2018-05-02
US10183006B2 (en) 2019-01-22
RS56196B1 (sr) 2017-11-30
US9962358B2 (en) 2018-05-08
CA2850391A1 (en) 2013-04-04
PL2760479T3 (pl) 2017-09-29
US10183003B2 (en) 2019-01-22
BR112014007357A2 (pt) 2017-04-04
MX2014003854A (es) 2014-10-17
US9254278B2 (en) 2016-02-09
AU2012316750B2 (en) 2017-08-31
US20180055807A1 (en) 2018-03-01
CN107271696A (zh) 2017-10-20
US8404215B1 (en) 2013-03-26
US20180235920A1 (en) 2018-08-23
JP6425746B2 (ja) 2018-11-21
CY1119028T1 (el) 2018-01-10
US20190125713A1 (en) 2019-05-02
US20130085179A1 (en) 2013-04-04
KR20180085823A (ko) 2018-07-27
US20180221324A1 (en) 2018-08-09
EP3263102A1 (en) 2018-01-03
ZA201401851B (en) 2018-05-30
MX366197B (es) 2019-06-25
JP2017067791A (ja) 2017-04-06
IL231732A0 (en) 2014-05-28
PT2760479T (pt) 2017-07-21
CL2014000783A1 (es) 2015-01-16
WO2013048558A2 (en) 2013-04-04
US20160202240A1 (en) 2016-07-14
MX2019006900A (es) 2019-09-04
WO2013048558A3 (en) 2014-04-03
ES2629859T3 (es) 2017-08-16
KR102019000B1 (ko) 2019-09-05
US9095559B2 (en) 2015-08-04
US20160199333A1 (en) 2016-07-14
JP6073898B2 (ja) 2017-02-01
US9962359B2 (en) 2018-05-08
US9326966B2 (en) 2016-05-03
HRP20171063T1 (hr) 2017-10-06
US10183002B2 (en) 2019-01-22
JP2014532179A (ja) 2014-12-04
US10045958B1 (en) 2018-08-14
US20180021293A1 (en) 2018-01-25
US20180015064A1 (en) 2018-01-18
US10045959B1 (en) 2018-08-14
US20180221325A1 (en) 2018-08-09
IL254134A0 (en) 2017-10-31
US20130210914A1 (en) 2013-08-15
IL231732A (en) 2017-09-28
US20160199332A1 (en) 2016-07-14
BR112014007357B1 (pt) 2022-12-06
US9999608B2 (en) 2018-06-19
AU2012316750A1 (en) 2014-03-27
US20180263948A1 (en) 2018-09-20
US20180021291A1 (en) 2018-01-25
EP2760479A4 (en) 2015-08-26
US20160081969A1 (en) 2016-03-24
US20210000784A1 (en) 2021-01-07
US20150335605A1 (en) 2015-11-26
EP2760479B1 (en) 2017-05-03
US10183005B2 (en) 2019-01-22
US10617665B2 (en) 2020-04-14
SI2760479T1 (sl) 2017-07-31

Similar Documents

Publication Publication Date Title
PT2760479T (pt) Métodos de monitorização da terapêutica com fármacos eliminadores de azoto
HK1212669A1 (zh) 用於在廢水處理中脫除氮的方法和裝置
HK1201145A1 (en) Methods and devices for treating hypertension
EP2757887A4 (en) PYRROLOPYRIDINONE COMPOUNDS AND METHOD FOR THE TREATMENT OF HIV
EP2668575A4 (en) METHOD AND APPARATUS FOR COMPILING REGULAR EXPRESSIONS
EP2691149A4 (en) SYSTEM AND METHOD FOR THE TREATMENT OF APNEA WITH EXCLUSIVE SWALLOWS
EP2737705A4 (en) METHOD AND APPARATUS FOR NON-INTER-TILE BUCKLE FILTERING
EP2755717A4 (en) APPARATUS AND METHOD FOR CARDIOPLEGIA
IL227710A0 (en) Wood injection device and methods
EP2731436A4 (en) AZAINDOL COMPOUNDS AND METHOD FOR THE TREATMENT OF HIV
EP2671583A4 (en) EXTERNALLY USED MEDICAMENT FOR THE TREATMENT OF SKIN DISEASES AND MANUFACTURING METHOD THEREFOR
EP2683836A4 (en) METHOD AND APPARATUS FOR PROCESSING CONTAINERS
EP2767089A4 (en) METHOD AND APPARATUS FOR LOOP FILTERING
IL229999B (en) Device and method for improving skin
EP2769550A4 (en) METHOD AND APPARATUS FOR LOOP FILTRATION
ZA201304360B (en) Method and device for treating biomass
ZA201500521B (en) Method and apparatus for treating a steel article
EP2844271A4 (en) PROCESSING METHOD AND AGENTS USEFUL THEREFOR
EP2745256A4 (en) APPARATUS AND METHOD FOR DETERMINING MEDICATION LOCATION
EP2753274A4 (en) LENS INJECTOR AND METHOD
PL2731653T3 (pl) Urządzenie do iniekcji i sposób jego wytwarzania
ZA201200851B (en) Anti-wart pharmaceutical composition and method for treating wart
EP2728504A4 (en) LICENSE ADMINISTRATION DEVICE AND LICENSE DELIVERY METHOD
PL2661706T3 (pl) Urządzenie oraz sposób zarządzania osobistym kanałem
EP2718427A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF GLIOBLASTOMES